{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-074513","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.923642+00:00","generated_at":"2026-06-13T16:50:47.593120+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Marker Therapeutics reports non-clinical data showing MT-401 + HMA synergy; awarded $2M NIH grant","bullets":["Non-clinical in vitro data: MT-401 after HMA (5'-Azacytidine) significantly decreased AML THP-1 cell growth vs. either agent alone, suggesting synergy.","NIH SBIR grant of $2 million will fund a nationwide multi-center Phase 2b trial of MT-401 with HMA pre-treatment in AML patients post-HSCT.","MT-401 targets four antigens (Survivin, PRAME, WT-1, NY-ESO-1); HMA upregulated Survivin expression in AML cells.","Company plans to incorporate findings into current AML clinical study; revised design details expected in Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-074513","json":"https://secwatch.observer/filing/0001104659-23-074513.json","markdown":"https://secwatch.observer/filing/0001104659-23-074513.md","text":"https://secwatch.observer/filing/0001104659-23-074513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923074513/0001104659-23-074513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923074513/tm2319618d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T16:50:47.593120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}